Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 57.44 Million USD | -19.11% |
| 2022 | 68.86 Million USD | 28.22% |
| 2021 | 53.7 Million USD | -38.9% |
| 2020 | 87.89 Million USD | 194.23% |
| 2019 | 29.87 Million USD | -33.86% |
| 2018 | 45.16 Million USD | -17.9% |
| 2017 | 55.01 Million USD | -31.14% |
| 2016 | 79.88 Million USD | -37.6% |
| 2015 | 128.02 Million USD | 24.78% |
| 2014 | 102.59 Million USD | 82.29% |
| 2013 | 56.28 Million USD | 26.2% |
| 2012 | 44.59 Million USD | 66.43% |
| 2011 | 26.79 Million USD | 74.41% |
| 2010 | 15.36 Million USD | -0.19% |
| 2009 | 15.39 Million USD | -28.83% |
| 2008 | 21.63 Million USD | 35.57% |
| 2007 | 15.95 Million USD | 134.75% |
| 2006 | 6.79 Million USD | 3.98% |
| 2005 | 6.53 Million USD | -2.84% |
| 2004 | 6.72 Million USD | -3.44% |
| 2003 | 6.96 Million USD | -55.8% |
| 2002 | 15.76 Million USD | 55.58% |
| 2001 | 10.13 Million USD | 44.87% |
| 2000 | 6.99 Million USD | 24.68% |
| 1999 | 5.61 Million USD | 17.12% |
| 1998 | 4.79 Million USD | 60.2% |
| 1997 | 2.99 Million USD | 104.79% |
| 1996 | 1.46 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 15.52 Million USD | 2.35% |
| 2024 Q2 | 17.45 Million USD | 15.79% |
| 2023 Q2 | 13.77 Million USD | -0.48% |
| 2023 FY | 55.7 Million USD | -19.11% |
| 2023 Q1 | 13.84 Million USD | -26.26% |
| 2023 Q4 | 15.16 Million USD | 6.57% |
| 2023 Q3 | 14.23 Million USD | 3.29% |
| 2022 Q4 | 18.77 Million USD | 18.65% |
| 2022 Q1 | 12.68 Million USD | 18.86% |
| 2022 FY | 68.86 Million USD | 28.22% |
| 2022 Q3 | 15.82 Million USD | -26.66% |
| 2022 Q2 | 21.57 Million USD | 70.04% |
| 2021 Q3 | 10.39 Million USD | -18.9% |
| 2021 Q4 | 10.67 Million USD | 2.66% |
| 2021 Q1 | 19.8 Million USD | -16.99% |
| 2021 Q2 | 12.82 Million USD | -35.27% |
| 2021 FY | 53.7 Million USD | -38.9% |
| 2020 FY | 87.89 Million USD | 194.23% |
| 2020 Q3 | 48.09 Million USD | 546.59% |
| 2020 Q2 | 7.43 Million USD | -10.42% |
| 2020 Q1 | 8.3 Million USD | 10.69% |
| 2020 Q4 | 23.86 Million USD | -50.38% |
| 2019 Q2 | 7.21 Million USD | -10.94% |
| 2019 FY | 29.87 Million USD | -33.86% |
| 2019 Q4 | 7.5 Million USD | 6.41% |
| 2019 Q3 | 7.04 Million USD | -2.34% |
| 2019 Q1 | 8.1 Million USD | 39.33% |
| 2018 FY | 45.16 Million USD | -17.9% |
| 2018 Q1 | 8.94 Million USD | -50.31% |
| 2018 Q2 | 20.63 Million USD | 130.58% |
| 2018 Q3 | 9.77 Million USD | -52.64% |
| 2018 Q4 | 5.81 Million USD | -40.47% |
| 2017 Q3 | 14.28 Million USD | 32.81% |
| 2017 FY | 55.01 Million USD | -31.14% |
| 2017 Q4 | 18 Million USD | 26.1% |
| 2017 Q2 | 10.75 Million USD | -10.18% |
| 2017 Q1 | 11.97 Million USD | -43.84% |
| 2016 Q3 | 25.67 Million USD | 69.14% |
| 2016 Q1 | 17.71 Million USD | -66.1% |
| 2016 Q4 | 21.31 Million USD | -16.97% |
| 2016 Q2 | 15.18 Million USD | -14.31% |
| 2016 FY | 79.88 Million USD | -37.6% |
| 2015 Q1 | 23.02 Million USD | -12.44% |
| 2015 FY | 128.02 Million USD | 24.78% |
| 2015 Q3 | 13.5 Million USD | -65.59% |
| 2015 Q4 | 52.24 Million USD | 286.91% |
| 2015 Q2 | 39.24 Million USD | 70.45% |
| 2014 Q2 | 25.42 Million USD | 7.37% |
| 2014 Q3 | 27.19 Million USD | 6.93% |
| 2014 Q4 | 26.29 Million USD | -3.29% |
| 2014 Q1 | 23.68 Million USD | 61.4% |
| 2014 FY | 102.59 Million USD | 82.29% |
| 2013 Q3 | 15.85 Million USD | 35.77% |
| 2013 Q1 | 14.08 Million USD | -11.45% |
| 2013 FY | 56.28 Million USD | 26.2% |
| 2013 Q4 | 14.67 Million USD | -7.44% |
| 2013 Q2 | 11.67 Million USD | -17.08% |
| 2012 Q3 | 13.86 Million USD | 52.88% |
| 2012 Q1 | 5.76 Million USD | 24.19% |
| 2012 FY | 44.59 Million USD | 66.43% |
| 2012 Q4 | 15.9 Million USD | 14.72% |
| 2012 Q2 | 9.06 Million USD | 57.28% |
| 2011 Q2 | 9.02 Million USD | 33.63% |
| 2011 FY | 26.79 Million USD | 74.41% |
| 2011 Q4 | 4.64 Million USD | -27.14% |
| 2011 Q3 | 6.37 Million USD | -29.43% |
| 2011 Q1 | 6.75 Million USD | 14.68% |
| 2010 Q1 | 3.34 Million USD | -3.88% |
| 2010 Q2 | 3.1 Million USD | -7.2% |
| 2010 Q3 | 3.02 Million USD | -2.77% |
| 2010 FY | 15.36 Million USD | -0.19% |
| 2010 Q4 | 5.89 Million USD | 95.07% |
| 2009 Q2 | 3.26 Million USD | -14.61% |
| 2009 Q3 | 4.82 Million USD | 47.61% |
| 2009 Q4 | 3.48 Million USD | -27.77% |
| 2009 FY | 15.39 Million USD | -28.83% |
| 2009 Q1 | 3.82 Million USD | -17.67% |
| 2008 Q3 | 5.3 Million USD | -11.64% |
| 2008 Q2 | 5.99 Million USD | 5.47% |
| 2008 Q1 | 5.68 Million USD | -18.21% |
| 2008 Q4 | 4.64 Million USD | -12.34% |
| 2008 FY | 21.63 Million USD | 35.57% |
| 2007 Q1 | 1.82 Million USD | -26.06% |
| 2007 Q3 | 3.57 Million USD | -1.03% |
| 2007 FY | 15.95 Million USD | 134.75% |
| 2007 Q2 | 3.6 Million USD | 98.08% |
| 2007 Q4 | 6.95 Million USD | 94.65% |
| 2006 Q4 | 2.46 Million USD | 63.94% |
| 2006 Q1 | 864 Thousand USD | -19.33% |
| 2006 Q3 | 1.5 Million USD | -23.55% |
| 2006 FY | 6.79 Million USD | 3.98% |
| 2006 Q2 | 1.96 Million USD | 127.55% |
| 2005 FY | 6.53 Million USD | -2.84% |
| 2005 Q4 | 1.07 Million USD | -43.6% |
| 2005 Q3 | 1.89 Million USD | 7.78% |
| 2005 Q2 | 1.76 Million USD | -2.27% |
| 2005 Q1 | 1.8 Million USD | -29.54% |
| 2004 FY | 6.72 Million USD | -3.44% |
| 2004 Q4 | 2.55 Million USD | 4.11% |
| 2004 Q3 | 2.45 Million USD | 177.74% |
| 2004 Q2 | 885 Thousand USD | 7.53% |
| 2004 Q1 | 823 Thousand USD | -12.17% |
| 2003 Q1 | 1.66 Million USD | -63.71% |
| 2003 FY | 6.96 Million USD | -55.8% |
| 2003 Q4 | 937 Thousand USD | -28.2% |
| 2003 Q3 | 1.3 Million USD | -57.42% |
| 2003 Q2 | 3.06 Million USD | 84.53% |
| 2002 Q3 | 3.52 Million USD | -21.46% |
| 2002 Q1 | 3.18 Million USD | -34.56% |
| 2002 FY | 15.76 Million USD | 55.58% |
| 2002 Q4 | 4.57 Million USD | 29.95% |
| 2002 Q2 | 4.48 Million USD | 40.91% |
| 2001 Q4 | 4.86 Million USD | 0.0% |
| 2001 FY | 10.13 Million USD | 44.87% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | 3.18 Million USD | 37.29% |
| 2001 Q2 | - USD | -100.0% |
| 2000 Q4 | 2.32 Million USD | 31.07% |
| 2000 FY | 6.99 Million USD | 24.68% |
| 2000 Q3 | 1.77 Million USD | 0.0% |
| 1999 FY | 5.61 Million USD | 17.12% |
| 1998 FY | 4.79 Million USD | 60.2% |
| 1997 FY | 2.99 Million USD | 104.79% |
| 1996 FY | 1.46 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -4201.233% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1039.221% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -94.363% |
| Nascent Biotech, Inc. | 2.22 Million USD | -2475.925% |
| Rebus Holdings, Inc. | 664 Thousand USD | -8550.602% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -54.178% |
| Qrons Inc. | 643.67 Thousand USD | -8823.73% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -14644.613% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -13725.007% |
| Skye Bioscience, Inc. | 13.54 Million USD | -323.988% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 33.813% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1067.975% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -21846.616% |
| SQZ Biotechnologies Company | 85.61 Million USD | 32.912% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1869.663% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -3724.492% |
| Mesoblast Limited | 5.9 Million USD | -873.229% |
| Marizyme, Inc. | 19.23 Million USD | -198.547% |
| Genus plc | 147.7 Million USD | 61.11% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -554.271% |
| Pharming Group N.V. | 225.49 Million USD | 74.527% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -2703.722% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -4181.631% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -588.812% |
| ContraFect Corporation | 56.88 Million USD | -0.969% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -1202.887% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -3784.357% |
| IMV Inc. | 37.7 Million USD | -52.324% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1958.518% |
| MultiCell Technologies, Inc. | 567.42 USD | -10122912.936% |
| ONE Bio Corp. | 6.44 Million USD | -791.387% |
| Accustem Sciences Inc. | 3.74 Million USD | -1433.197% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 33.167% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -10697.764% |
| Q BioMed Inc. | 3.43 Million USD | -1571.406% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -132.409% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -2086.09% |
| Biomind Labs Inc. | 994.18 Thousand USD | -5677.614% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 42.173% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -3164.234% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -755.014% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -2980.934% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 229860.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -258.77% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -3030.083% |
| GB Sciences, Inc. | 1.42 Million USD | -3943.621% |
| Alpha Cognition Inc. | 9.7 Million USD | -491.823% |
| HST Global, Inc. | 140.9 Thousand USD | -40664.476% |
| CSL Limited | 3.44 Billion USD | 98.335% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -5006.186% |
| Halberd Corporation | 74.84 Thousand USD | -76648.35% |
| Enzolytics Inc. | 2.17 Million USD | -2535.458% |
| Agentix Corp. | 1.37 Million USD | -4087.334% |
| Resverlogix Corp. | 12.71 Million USD | -351.857% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -1473.394% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 96.254% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -5401.916% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -2288.423% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -3536.928% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1586.941% |
| AVAX Technologies, Inc. | 7.31 Million USD | -685.745% |
| Zenith Capital Corp. | 8.94 Million USD | -542.29% |
| Genscript Biotech Corporation | 825.34 Million USD | 93.04% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -329617.008% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -2239.413% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -33390.954% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -2890.256% |
| Kadimastem Ltd | 2.41 Million USD | -2283.292% |
| Helix BioMedix, Inc. | 1.97 Million USD | -2812.729% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -428.573% |
| BioStem Technologies, Inc. | 22.97 Million USD | -150.013% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -31549.999% |
| LadRx Corporation | 3.81 Million USD | -1406.903% |
| Cell Source, Inc. | 4.32 Million USD | -1227.986% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -6119.749% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -6119.749% |
| NovAccess Global Inc. | 2.46 Million USD | -2228.56% |
| Affymax, Inc. | 39.38 Million USD | -45.839% |
| Itoco Inc. | 919.14 Thousand USD | -6149.3% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -1255.224% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -5033.155% |
| Mobile Lads Corp. | 554.54 Thousand USD | -10258.023% |
| CytoDyn Inc. | 18.05 Million USD | -218.086% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -228117.251% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -25999.837% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -3945.663% |
| SYBLEU INC | 160.87 Thousand USD | -35604.518% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -3062.438% |
| International Stem Cell Corporation | 5.27 Million USD | -989.736% |
| Bioxytran, Inc. | 3.82 Million USD | -1403.607% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -109014.395% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -282257.568% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -58.385% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -3450.062% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -7706.098% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1746.352% |
| Neutra Corp. | 243.82 Thousand USD | -23458.266% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -229.037% |
| PureTech Health plc | 144.59 Million USD | 60.276% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -180.333% |
| IXICO plc | 4.7 Million USD | -1120.31% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -552.95% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 51.218% |
| CSL Limited | 3.89 Billion USD | 98.525% |
| Cellectis S.A. | 97.32 Million USD | 40.978% |